Medtech has long been a highly profitable area for investors. As the space has matured and grown more competitive, however, investors have had to become more cautious when picking stocks in this high-growth space. 

Over the past five years, for instance, industry giants like Medtronic have lagged the broader markets from a capital appreciation standpoint due to headwinds emanating from legacy portfolios, while up-and-coming device makers such as the diabetes care company DexCom have yielded life-changing gains for shareholders.  

Image source: Getty Images.

Continue reading

Source Fool.com